Literature DB >> 9831786

The role of antibiotics in the treatment of chronic prostatitis: a consensus statement.

T E Bjerklund Johansen1, R N Grüneberg, J Guibert, A Hofstetter, B Lobel, K G Naber, J Palou Redorta, P J van Cangh.   

Abstract

Practical guidelines for the diagnosis and treatment of chronic prostatitis are presented. Chronic prostatitis is classified as chronic bacterial prostatitis (culture-positive) and chronic inflammatory prostatitis (culture-negative). If chronic bacterial prostatitis is suspected, based on relevant symptoms or recurrent UTIs, underlying urological conditions should be excluded by the following tests: rectal examination, midstream urine culture and residual urine. The diagnosis should be confirmed by the Meares and Stamey technique. Antibiotic therapy is recommended for acute exacerbations of chronic prostatitis, chronic bacterial prostatitis and chronic inflammatory prostatitis, if there is clinical, bacteriological or supporting immunological evidence of prostate infection. Unless a patient presents with fever, antibiotic treatment should not be initiated immediately except in cases of acute prostatitis or acute episodes in a patient with chronic bacterial prostatitis. The work-up, with the appropriate investigations should be done first, within a reasonable time period which, preferably, should not be longer than 1 week. During this period, nonspecific treatment, such as appropriate analgesia to relieve symptoms, should be given. The minimum duration of antibiotic treatment should be 2-4 weeks. If there is no improvement in symptoms, treatment should be stopped and reconsidered. However, if there is improvement, it should be continued for at least a further 2-4 weeks to achieve clinical cure and, hopefully, eradication of the causative pathogen. Antibiotic treatment should not be given for 6-8 weeks without an appraisal of its effectiveness. Currently used antibiotics are reviewed. Of these, the fluoroquinolones ofloxacin and ciprofloxacin are recommended because of their favourable antibacterial spectrum and pharmacokinetic profile. A number of clinical trials are recommended and a standard study design is proposed to help resolve some outstanding issues.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9831786     DOI: 10.1159/000019784

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  27 in total

Review 1.  Interventions for chronic abacterial prostatitis.

Authors:  C McNaughton; R Mac Donald; T Wilt
Journal:  Cochrane Database Syst Rev       Date:  2001

2.  Prostatitis.

Authors:  J Curtis Nickel
Journal:  Can Urol Assoc J       Date:  2011-10       Impact factor: 1.862

3.  Fluoroquinolone Antimicrobial Agents in the Treatment of Prostatitis and Recurrent Urinary Tract Infections in Men.

Authors:  F M E Wagenlehner; K G Naber
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.725

4.  Excessive antibiotic use in men with prostatitis.

Authors:  Brent C Taylor; Siamak Noorbaloochi; Mary McNaughton-Collins; Christopher S Saigal; Min-Woong Sohn; Michel A Pontari; Mark S Litwin; Timothy J Wilt
Journal:  Am J Med       Date:  2008-05       Impact factor: 4.965

Review 5.  Chronic prostatitis/chronic pelvic pain syndrome in elderly men: toward better understanding and treatment.

Authors:  Michel A Pontari
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

6.  A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Jianxin Wang; Dongliang Yan; Kuixiang Liang; Zhonghua Xu
Journal:  Int Urol Nephrol       Date:  2015-11-17       Impact factor: 2.370

Review 7.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  A host defense mechanism involving CFTR-mediated bicarbonate secretion in bacterial prostatitis.

Authors:  Chen Xie; Xiaoxiao Tang; Wenming Xu; Ruiying Diao; Zhiming Cai; Hsiao Chang Chan
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

Review 9.  [Chronic prostatitis. Chronic pelvic pain syndrome].

Authors:  O Moormann; B Planz; H-P Caspers; U Wesselmann
Journal:  Schmerz       Date:  2004-04       Impact factor: 1.107

10.  [Prostatitis syndrome].

Authors:  Florian M E Wagenlehner; H Schneider; W Weidner
Journal:  Urologe A       Date:  2007-02       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.